Abstract
Glycosylation of viral envelope proteins is important for infectivity and interaction with host immunity, however, our current knowledge of the functions of glycosylation is largely limited to N-glycosylation because it is difficult to predict and identify site-specific O-glycosylation. Here, we present a novel proteome-wide discovery strategy for O-glycosylation sites on viral envelope proteins using herpes simplex virus type 1 (HSV-1) as a model. We identified 74 O-linked glycosylation sites on 8 out of the 12 HSV-1 envelope proteins. Two of the identified glycosites found in glycoprotein B were previously implicated in virus attachment to immune cells. We show that HSV-1 infection distorts the secretory pathway and that infected cells accumulate glycoproteins with truncated O-glycans, nonetheless retaining the ability to elongate most of the surface glycans. With the use of precise gene editing, we further demonstrate that elongated O-glycans are essential for HSV-1 in human HaCaT keratinocytes, where HSV-1 produced markedly lower viral titers in HaCaT with abrogated O-glycans compared to the isogenic counterpart with normal O-glycans. The roles of O-linked glycosylation for viral entry, formation, secretion, and immune recognition are poorly understood, and the O-glycoproteomics strategy presented here now opens for unbiased discovery on all enveloped viruses.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Animals
-
Flow Cytometry
-
Glycomics
-
Glycoproteins / metabolism
-
Glycosylation
-
Herpesvirus 1, Human / metabolism*
-
Humans
-
Immunohistochemistry
-
Mass Spectrometry / methods*
-
Polymerase Chain Reaction
-
Proteomics / methods*
-
Viral Envelope Proteins / metabolism*
Substances
-
Glycoproteins
-
Viral Envelope Proteins
Grants and funding
This work was in part supported by The Danish Research Councils (1331-00133B),
http://ufm.dk/en/research-and-innovation/funding-programmes-for-research-and-innovation/find-danish-funding-programmes (IB, SD, HHW); a programme of excellence 2016 (Copenhagen as the next leader in precise genetic engineering CDO2016: 2016CDO04210) from the University of Copenhagen
http://www.cdo.ku.dk/http://research.ku.dk/strengths/excellence-programmes/ (IB, HHW); The Danish National Research Foundation (DNRF107)
http://dg.dk/en/ (IB, HHJ, SYV, HHW); Carl Emil Friis og hustru Olga Doris Friis Foundation (HHW); The Lundbeck Foundation
http://www.lundbeckfoundation.com/ (HHW), A.P. Møller og Hustru Chastine Mc-Kinney Møllers Fond til Almene Formaal
http://www.apmollerfonde.dk/ (HHW), Kirsten og Freddy Johansen Fonden
http://www.kf-j.dk/ (HHW), Mizutani Foundation
http://www.mizutanifdn.or.jp/ (SYV) and The Novo Nordisk Foundation
http://www.novonordiskfonden.dk/en (HHW). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.